Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Stock Short Interest Declines 76.4%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totaling 1,699 shares, a decrease of 76.4% from the September 30th total of 7,209 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 8,969 shares, the short-interest ratio is presently 0.2 days.

Fidelity Disruptive Medicine ETF Stock Up 2.2%

Shares of NASDAQ FMED traded up $0.72 during trading on Wednesday, reaching $33.24. 9,445 shares of the company traded hands, compared to its average volume of 10,647. The firm has a 50 day simple moving average of $31.69 and a 200-day simple moving average of $27.72. The stock has a market capitalization of $53.18 million, a PE ratio of 41.33 and a beta of 0.76. Fidelity Disruptive Medicine ETF has a 52-week low of $23.48 and a 52-week high of $33.30.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Fidelity Disruptive Medicine ETF stock. Root Financial Partners LLC bought a new position in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,291 shares of the company’s stock, valued at approximately $42,000. Root Financial Partners LLC owned about 0.08% of Fidelity Disruptive Medicine ETF at the end of the most recent quarter.

Fidelity Disruptive Medicine ETF Company Profile

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.